Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Johnson & Johnson (JNJ) Stock Price & Analysis

JNJ Stock Chart & Stats

€246.70€0.75(0.30%)
At close: 5:30 PM GMT+1
€220€230€2403 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 246.70 - EUR 251.65
52-Week Range
EUR 160.40 - EUR 251.65
Previous Close
EUR 245.95
Volume
1,325
Average Volume (3M)
2,360
Market Cap
EUR 588.88B
Enterprise Value
EUR 691.53B
Total Cash (Recent Filing)
EUR 17.23B
Total Debt (Recent Filing)
EUR 44.65B
Price to Earnings (P/E)
41.4
Beta
0.14
Next Earnings
Jan 26, 2027 (Est.)
EPS Estimate
2.6
Next Dividend Ex-Date
Nov 24, 2026
Dividend Yield
1.83%

Bulls Say, Bears Say

Bulls Say

Innovative Medicine Growth

Strong growth across oncology, immunology, neuroscience, and other therapeutic areas indicates broad product adoption rather than dependence on a single medicine. Multiple expanding brands can sustain revenue momentum, support reinvestment, and help offset future product-level erosion.

Reliable Cash Generation

Consistently positive operating and free cash flow gives Johnson & Johnson substantial capacity to fund research, business development, dividends, and debt service internally. This recurring cash engine strengthens resilience and supports continued investment through changing healthcare cycles.

Innovation And Portfolio Expansion

Investment in next-generation oncology platforms expands the pipeline beyond current products and targets difficult-to-treat cancers with significant unmet need. Although costly initially, these capabilities can reinforce Johnson & Johnson’s long-term competitive position and future growth options.

Bears Say

Margin Pressure

The decline in adjusted margins shows that product mix, amortization, research spending, and transaction costs are currently absorbing part of the company’s operating leverage. Persistent pressure would reduce the amount of revenue growth converting into earnings and cash.

Higher Debt And Slower Free Cash Flow

Higher debt alongside weaker recent free-cash-flow growth reduces financial flexibility compared with prior lower-leverage periods. The balance sheet remains generally sound, but less conservative coverage can constrain capital allocation and increase sensitivity to execution or transaction costs.

Biosimilar Erosion

STELARA’s decline demonstrates how biosimilar competition can erode established pharmaceutical revenue after exclusivity weakens. Continued pressure on mature franchises could offset newer-product growth, requiring sustained pipeline productivity and commercial execution to preserve overall expansion.

Johnson & Johnson News

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was €160.40 and its highest was €251.65 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is €588.88B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s next earnings report is estimated for Jan 26, 2027 (not yet confirmed), which is in 85 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 13, 2026. The company reported €2.318 earnings per share for the quarter, beating the consensus estimate of €2.258 by €0.061.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of €1.201 which represents an annual dividend yield of 1.83%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.60.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,310,300 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of €2.318 in its last earnings report, beating expectations of €2.258. Following the earnings report the stock price went down -5.609%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Hedge funds hold Johnson & Johnson shares: the largest hedge-fund position in Johnson & Johnson is 514,070,861 shares, and hedge funds increased their holdings by 3.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology